GenSight announces first enrolled patient in Phase 3 GS010 trials
GenSight Biologics S.A. announced this week that the first patient has enrolled in the company’s two parallel Phase 3 trials for GS010, a medicine designed to treat Leber’s Hereditary Optic Neuropathy (LHON). Read More »